Facebook
Twitter
LinkedIn
Forward
Genetics in Clinical Cancer Care: Controversies, Insights & Scalable Solutions BRCA2-Associated Male Breast Cancer: Should There Be a Different Surgical Approach?
Type: Podcast
This activity will provide an interdisciplinary educational forum in which to update state-of-the-art science in translational genomics and developmental therapeutics, discuss real-world cases, curate interesting pedigrees and prepare case summaries to disseminate new knowledge and evidence-based clinical management of high-risk patients and their family members. The goal is to improve detection of cancer syndromes and accelerate progress in drug development to prevent cancer morbidity and mortality in ALL populations.
Target Audience
This activity has been designed for physicians, physician assistants, advanced nurse practitioners, genetic counselors, nurses, pharmacists and other health care professionals involved in providing interdisciplinary cancer genetics risk assessment services or initiating such services in their health care system. Special efforts will be made to meet the needs of clinicians practicing in non-academic centers and geographically and/or socioeconomically underserved communities.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review advanced concepts in genetics, genomics, and next generation Omics technologies;
- Debate controversies in cancer risk assessment and genetic testing including integration of polygenic risk score into comprehensive cancer risk assessment;
- Recognize advances in BRCA research with special emphasis on progress in treatment of BRCA associated cancers;
- Discuss integration of novel cancer therapies based on somatic genomic alterations in solid tumors and hematologic malignancies that may reveal germline mutations e.g MLH1 and BRCA mutations into the practice of oncology;
- Understand emerging concepts in Men’s health;
- Develop a globally informed perspective on Precision Oncology;
- Discuss emerging concepts in Artificial Intelligence and Deep Learning to advance population health management;
- Understand ethical, legal and social implications of emerging technologies for early detection of cancer in diverse populations.
FACULTY
Nora T. Jaskowiak, MD
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School Of Medicine designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professions Credit
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
REGISTRATION: For additional information on this podcast, click the button below or download the Convey MED app!
Please login or create an account to proceed.